Treace Medical Concepts/$TMCI

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Treace Medical Concepts

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.

Ticker

$TMCI
Primary listing

Industry

Health Care Equipment & Supplies

Employees

477

ISIN

US89455T1097

TMCI Metrics

BasicAdvanced
$377M
-
-$0.85
0.80
-

What the Analysts think about TMCI

Analyst ratings (Buy, Hold, Sell) for Treace Medical Concepts stock.

Bulls say / Bears say

Treace Medical Concepts reported Q1 2025 revenue of $52.6 million, a 3% year-over-year increase, and improved its net loss by 15% to $(15.9) million, indicating positive financial momentum. (stocktitan.net)
The company has expanded its product portfolio with limited releases of Nanoplasty™, Percuplasty™ 3D MIS Osteotomy Systems, and SpeedMTP™ MTP Fusion System, potentially driving future revenue growth. (stocktitan.net)
Analysts have set an average 12-month price target of $10.21 for TMCI, suggesting a potential upside from its current trading price. (americanbankingnews.com)
Treace Medical Concepts filed a patent infringement lawsuit against Zimmer Biomet Holdings and Paragon 28, which could lead to prolonged legal battles and associated costs. (stocktitan.net)
The company reported a net loss of $(15.9) million in Q1 2025, indicating ongoing profitability challenges. (stocktitan.net)
Increased competition from minimally invasive surgery (MIS) osteotomy solutions and knockoffs of Treace's Lapiplasty® products have led to a downward revision of the company's 2024 revenue guidance. (markets.businessinsider.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.

TMCI Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

TMCI Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TMCI

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs